Results 281 to 290 of about 104,732 (315)

Chemokine receptor CCR5 in interferon-treated multiple sclerosis

Acta Neurologica Scandinavica, 2007
To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta).The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta ...
Sellebjerg, F, Kristiansen, Thomas Birk, Wittenhagen, P, Garred, P, Eugen-Olsen, J, Frederiksen, J L, Sørensen, Torben Lykke   +6 more
openaire   +4 more sources

Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor

International Immunopharmacology, 2007
The species selectivity of four structurally different compounds, SCH-351125, E-913, TAK-779 and UK-427857 has been examined using cloned human, rhesus, and mouse CCR5 receptors. SCH-351125 and E-913 potently inhibited the binding of [125I]-CCL3 to human CCR5, but their inhibitory activities against rhesus CCR5 were more than 10-fold weaker.
Yuji Saita, Yasuaki Shimizu, Mitsuhiro Kondo   +2 more
openaire   +3 more sources

Heterodimerization and cross-desensitization between the μ-opioid receptor and the chemokine CCR5 receptor

European Journal of Pharmacology, 2004
Cross-desensitization between micro-opioid receptor agonists and CC chemokines was shown to occur in immune cells and in the central nervous system. However, these cells do not permit examination of potential mechanisms at cellular levels due to low levels and mixed populations of receptors.
Chen, Chongguang, Li, Jin, Bot, György, Rogers, Thomas J., Liu-Chen, Lee-Yuan, Szabó, Imre   +5 more
openaire   +3 more sources

Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravis

International Journal of Molecular Medicine, 2003
The aim of this study was to examine the association of human autoimmune myasthenia gravis (MG) with two DNA polymorphisms of the chemokine receptors CCR5-Delta 32 and CCR2-64I. CCR2 and CCR5 interact primarily with the human CC family ligands CCL2 (formerly called monocyte chemoattractant protein; MCP-1), CCL3 and CCL4 (macrophage inflammatory protein-
Peter Hjelmström, Xiaoyan Zhao, Ann-Kari Lefvert, Mehran Ghaderi, Baback Gharizadeh, Ritva Pirskanen, Pål Nyrén   +6 more
openaire   +3 more sources

Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection

Nature Network Boston, 2000
M. Mack, A. Kleinschmidt, H. Brühl, C. Klier, Peter J. Nelson, J. Cihak, J. Plachý, M. Stangassinger, V. Erfle, D. Schlöndorff   +9 more
semanticscholar   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

CCR5 Chemokine Receptor

2007
Travis Lewis, Howard Gendelman
openaire   +1 more source

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly